Dr. Bodei is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1275 York Ave
New York, NY 10065Phone+1 212-639-5387Fax+1 212-717-3263- Is this information wrong?
Education & Training
University of GroningenPhD, 2007 - 2009- University of PisaResidency in Nuclear Medicine, Cum Laude, 1995 - 1999
University of Pisa Faculty of MedicineClass of 1995
Certifications & Licensure
NY State Medical License 2016 - 2025
NJ State Medical License 2021 - 2025- American Board of Nuclear Medicine Nuclear Medicine
Clinical Trials
- Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver Start of enrollment: 2020 Sep 02
- A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer Start of enrollment: 2021 Sep 14
Roles: Contact
Publications & Presentations
PubMed
- Development of a multigenomic liquid biopsy (PROSTest) for prostate cancer in whole blood.Mark Kidd, Ignat A Drozdov, Martin Boegemann, Jolanta Kunikowska, Anna Malczewska, Christof Bernemann, Srinivas V Koduru, Kambiz Rahbar, Irvin M Modlin, Lisa Bodei> ;The Prostate. 2024 Apr 3
- How Can Radiopharmaceutical Therapies Reach Their Full Potential? Improving Dose Reporting and Phase I Clinical Trial Design.Ana P Kiess, Joseph O'Donoghue, Carlos Uribe, Lisa Bodei, Robert F Hobbs, Jacob Hesterman, Adam L Kesner, George Sgouros> ;Journal of Clinical Oncology. 2024 Mar 14
- Peptide receptor radionuclide therapy with 177Lu- or 90Y-SSTR peptides in malignant pheochromocytomas (PCCs) and paragangliomas (PGLs): results from a single instituti...Rubino, M., Di Stasio, G., Papi, S., Rocca, P., Ferrari, M., Fodor, C., Bagnardi, V., Frassoni, S., Mei, R., Fazio, N., Ceci, F., Grana, C., Bodei, L.> ;Endocrine. 2024 Feb 7
- Join now to see all
Journal Articles
- Biodistribution and Radiation Dose Estimates for 68Ga-DOTA-JR11 in Patients with Metastatic Neuroendocrine TumorsSimone Krebs, Lisa Bodei, Diane Reidy, Bradley J Beattie, Wolfgang A Weber, European Journal of Nuclear Medicine and Molecular Imaging
- Blood mRNA Measurement (NETest) for Neuroendocrine Tumors Diagnosis of Image-Negative Liver Metastatic DiseaseIrvin M Modlin, Lisa Bodei, The Journal of Clinical Endocrinology and Metabolism
Lectures
- PRRT neuroendocrine tumor response assessment using blood transcript analysis: The NETest.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
- Peptide receptor radionuclide therapy (PRRT) transcriptomic signature in blood for prediction of 177lu-octreotate efficacy.2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Authored Content
- Observations from a Biomarker Perspective at ASCO GIFebruary 2020
- Observations from a Biomarker Perspective at ASCO GIFebruary 2020
Press Mentions
Blood Biomarkers Predict Neuroendocrine Tumor Response to Radiopharmaceutical TherapyApril 7th, 2023- A Promising New Therapy for Advanced Prostate CancerJune 3rd, 2021
- ASCO 2021: PSMA-Targeted Radioligand Therapy Improves Survival in Metastatic Prostate CancerJune 3rd, 2021
- Join now to see all
Hospital Affiliations
Memorial Sloan Kettering Cancer CenterNew York, New York
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
